Drugs / Imurel®
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03323476 Comparator | Feb 2018 → Mar 2028 expected | anti-neutrophil cytoplasmic antibody-associated vasculitis, end stage renal failure | Centre Hospitalier Departemental Vendee | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Imurel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03323476 ↗ |